Cornerstone Robotics Secures $200M Oversubscribed Funding to Accelerate Global Expansion of Surgical Robots
Want to read in a language you're more familiar with?
On November 10, China-based surgical robotics innovator Cornerstone Robotics announced it has raised an oversubscribed US$200 million in its latest financing round.
On November 10, China-based surgical robotics innovator Cornerstone Robotics announced it has raised an oversubscribed US$200 million in its latest financing round. The round was led by Hong Kong Investment Corporation (HKIC)—the Hong Kong SAR government’s sovereign investment arm—and joined by a global strategic investor, a top sovereign wealth fund, and existing backers including Qiming Venture Partners, Gaorong Capital, and others.
The new capital will accelerate commercialization in China and overseas, and support next-generation product development and clinical approvals. The participation of a major global strategic investor and a leading sovereign wealth fund strengthens the company’s global market access, regulatory pathways, and regional partnerships. Continued investment from long-time shareholders signals strong confidence in the company’s technology roadmap and long-term potential.
Founded in 2019, Cornerstone Robotics has rapidly grown into one of China’s leading surgical robotics unicorns. Its flagship laparoscopic system, Sentire®, has been approved by China’s NMPA and adopted by top hospitals in mainland China, Hong Kong, and Europe. The company has built a fully integrated supply chain—covering robotic systems, imaging, energy platforms, and instruments—with 100% in-house production of core components.
In 2025, Cornerstone and The Chinese University of Hong Kong jointly developed the world’s first multifunctional embodied-intelligence platform for surgical robots, successfully completing the world’s first autonomous surgical demonstration on the Sentire® system.
CEO Professor Ou Guowei said the new financing marks a major milestone: “With strong support from new and existing investors, especially HKIC, we are positioned to accelerate commercialization and global expansion, bringing high-quality, accessible surgical robotics solutions to patients worldwide.”
